Bridging the Gap: How the Global Pediatric Clinical Trial Market is Expanding Access to Care
The pediatric clinical trial market is poised for significant growth, projected to expand at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2034. According to recent industry analysis, the market value is expected to surge from USD 17,918.1 million in 2024 to an impressive USD 31,661.0 million by 2034. This follows a robust growth period from 2019 to 2023, where the market expanded at a CAGR of 6.5%, reaching USD 16,831.0 million in 2023.
Pediatric clinical trials are essential for developing safe and effective treatments tailored for children, addressing a critical need in healthcare. This market growth is driven by increased research and development activities, rising investments in pediatric healthcare, and growing awareness about the importance of specialized clinical trials for children.
Get your PDF Sample Report:
https://www.futuremarketinsigh....ts.com/reports/sampl
The therapeutic area category in oncology placed second in terms of global sales share in 2021. Globally, cancer is the leading cause of mortality. By 2040, 291,000 more cases of cancer among children under the age of 19 are expected to be reported. The number of pediatric clinical trials is rising globally as a result of hospitals and other institutions concentrating on the development of therapeutic medications in response to the rising number of cases of juvenile cancer worldwide.
The worldwide market for pediatric clinical trials may be hampered for a number of reasons despite all of these growing factors. It is projected that the market for pediatric clinical trials would grow slowly due to the large number of studies that terminate for various reasons.
Pivotal Pediatric Clinical Trial Providers:
Synteract
ICON Plc.
Syneos Health
Medpace, Inc
PPD Inc.
Premier Research
LabCorp Drug Development
QPS Holding
Pfizer Inc.
The Emmes Company, LLC
IQVIA Inc.
Key Market Segmentation:
By Area:
Oncology
Infectious Diseases
Cardiovascular Diseases
Metabolic Diseases
Respiratory Diseases
Diabetes
HIV
Others
By Sponsor:
Industry
Government Organizations
Non-Government Organizations
Associations
Others
By Phases:
Phase 1
Phase 2
Phase 3
Phase 4
By Region:
North America
Latin America
East Asia
South Asia & Pacific
Western Europe
Eastern Europe
MEA
